Tempest Therapeutics Inc (NAS:TPST)

$ 1.42 -0.04 (-2.74%) Market Cap: 35.80 Mil Enterprise Value: 24.93 Mil PE Ratio: 0 PB Ratio: 2.05 GF Score: 36/100

Tempest Therapeutics Inc To Discuss Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma Call Transcript
Oct 11, 2023
Tempest Therapeutics Inc at HC Wainwright Investment Conference - New York Transcript
Sep 11, 2023
Tempest Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 15, 2023
Tempest Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Tempest Therapeutics Inc To Discuss Phase 1b/2 Combination Study of TPST-1120 in First-Line HCC Data Call Transcript
Apr 28, 2023
Tempest Therapeutics Inc at Piper Sandler Healthcare Conference Transcript
Nov 29, 2022
Tempest Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 17, 2022
Tempest Therapeutics Inc At ASCO Call Transcript
Jun 05, 2022
Millendo Therapeutics Inc And Tempest Therapeutics Inc Merger - M&A Call Transcript
Mar 29, 2021

Tempest Therapeutics Inc at Piper Sandler Healthcare Conference Transcript

Nov 29, 2022 / 04:30PM GMT

Release Date Price: $1.61 (-5.85%)

Transcript

James Yoo

Piper Sandler & Co. - Analyst

My name is James Yoo. I'm a healthcare strategist at Piper Sandler. Before I begin, I've been asked to draw your attention to certain disclosures regarding the relationship between Piper Sandler and Tempest posted in the back of the room and at the registration desk. As you know, Tempest is developing first-in-class, targeted, and immune-mediated cancer therapies, including TPST-1120, targeting PPAR-alpha; TPST-1495, targeting the prostaglandin pathway; and a preclinical TREX program.

Joining us from Tempest are CEO Stephen Brady; Tom Dubensky, Ph.D.; and Chief Medical Officer, Sam Whiting, Ph.D. Thank you all for joining us.

Stephen Brady

Tempest Therapeutics, Inc. - CEO & Director

Thank you, James.

Tom Dubensky

Tempest Therapeutics, Inc. - President & Director

Thank you.

Questions & Answers

James Yoo

Piper Sandler & Co. - Analyst

Absolutely. Maybe let's just jump in with TPST-1120, which

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.